Journal article · 2021 · Open access

Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine

Lara Scheherazade Milane, Mansoor M. Amiji

Drug Delivery and Translational Research, 11(4), 1309–1315 · Published 29 January 2021 · DOI 10.1007/s13346-021-00911-y

Open PDFView at the publisherCite this paper

In brief

“Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine” is a 2021 journal article by Lara Scheherazade Milane and Mansoor M. Amiji, published in Drug Delivery and Translational Research. OpenAlex counts 135 citations as of 22 November 2026, which puts it in the top 1% of works published in 2021 by citations. It is open access: the full text is free to read at Drug Delivery and Translational Research.

Citations
135
Most cited in
2022 (40)
Field-weighted impact
6.60
References
15
Authors
2

Abstract

One year after the first human case of SARS-CoV-2, two nanomedicine-based mRNA vaccines have been fast-tracked, developed, and have received emergency use authorization throughout the globe with more vaccine approvals on the heels of these first two. Several SARS-CoV-2 vaccine compositions use nanotechnology-enabled formulations. A silver lining of the COVID-19 pandemic is that the fast-tracked vaccine development for SARS-CoV-2 has advanced the clinical translation pathway for nanomedicine drug delivery systems. The laboratory science of lipid-based nanoparticles was ready and rose to the clinical challenge of rapid vaccine development. The successful development and fast tracking of SARS-CoV-2 nanomedicine vaccines has exciting implications for the future of nanotechnology-enabled drug and gene delivery; it demonstrates that nanomedicine is necessary and critical to the successful delivery of advanced molecular therapeutics such as nucleic acids, it is establishing the precedent of safety and the population effect of phase four clinical trials, and it is laying the foundation for the clinical translation of more complex, non-lipid nanomedicines. The development, fast-tracking, and approval of SARS-CoV-2 nanotechnology-based vaccines has transformed the seemingly daunting challenges for clinically translating nanomedicines into measurable hurdles that can be overcome. Due to the tremendous scientific achievements that have occurred in response to the COVID-19 pandemic, years, perhaps even decades, have been streamlined for certain translational nanomedicines.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Milane, L. S., & Amiji, M. M. (2021). Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Delivery and Translational Research, 11(4), 1309–1315. https://doi.org/10.1007/s13346-021-00911-y

MLA 9

Milane, Lara Scheherazade, and Mansoor M. Amiji. “Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.” Drug Delivery and Translational Research, vol. 11, no. 4, 2021, pp. 1309–1315. https://doi.org/10.1007/s13346-021-00911-y.

Chicago

Milane, Lara Scheherazade and Mansoor M. Amiji. 2021. “Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.” Drug Delivery and Translational Research 11 (4): 1309–1315. https://doi.org/10.1007/s13346-021-00911-y.

Harvard

Milane, L. S. and Amiji, M. M. (2021) ‘Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine’, Drug Delivery and Translational Research, 11(4), pp. 1309–1315. doi:10.1007/s13346-021-00911-y.

IEEE

L. S. Milane and M. M. Amiji, “Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine,” Drug Delivery and Translational Research, vol. 11, no. 4, pp. 1309–1315, 2021, doi: 10.1007/s13346-021-00911-y.

BibTeX

@article{milane2021clinical,
  title     = {{Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine}},
  author    = {Milane, Lara Scheherazade and Amiji, Mansoor M.},
  journal   = {Drug Delivery and Translational Research},
  year      = {2021},
  volume    = {11},
  number    = {4},
  pages     = {1309--1315},
  doi       = {10.1007/s13346-021-00911-y},
  url       = {https://doi.org/10.1007/s13346-021-00911-y}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20212929
20224040
20231717
20242222
20251313
20261414

Its field-weighted citation impact is 6.60: it has been cited 6.60 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery

  • COVID-19 mRNA vaccine
  • lipid nanoparticles
  • nanomedicine
  • clinical translation
  • vaccine approval
  • emergency use authorization
  • COVID-19 pandemic
  • nucleic acid delivery

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Milane, L. S., & Amiji, M. M. (2021). Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Delivery and Translational Research, 11(4), 1309–1315. https://doi.org/10.1007/s13346-021-00911-y

How many times has this paper been cited?

135 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Drug Delivery and Translational Research: sign in and open the PDF from this page.

Who wrote this paper?

Lara Scheherazade Milane, Mansoor M. Amiji.

What is the DOI of this paper?

10.1007/s13346-021-00911-y, permanently at https://doi.org/10.1007/s13346-021-00911-y. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.